Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Resource Type
Article
Authors
San-Miguel, Jesús F ; Hungria, Vânia T M ; Yoon, Sung-Soo ; Beksac, Meral ; Dimopoulos, Meletios Athanasios ; Elghandour, Ashraf ; Jedrzejczak, Wieslaw Wiktor ; Günther, Andreas ; Nakorn, Thanyaphong Na ; Siritanaratkul, Noppadol ; Corradini, Paolo ; Chuncharunee, Suporn ; Lee, Je-Jung ; Schlossman, Robert L ; Shelekhova, Tatiana ; Yong, Kwee ; Tan, Daryl ; Numbenjapon, Tontanai ; Cavenagh, Jamie D ; Hou, Jian ; LeBlanc, Richard ; Nahi, Hareth ; Qiu, Lugui ; Salwender, Hans ; Pulini, Stefano ; Moreau, Philippe ; Warzocha, Krzysztof ; White, Darrell ; Bladé, Joan ; Chen, WenMing ; de la Rubia, Javier ; Gimsing, Peter ; Lonial, Sagar ; Kaufman, Jonathan L ; Ocio, Enrique M ; Veskovski, Ljupco ; Sohn, Sang Kyun ; Wang, Ming-Chung ; Lee, Jae Hoon ; Einsele, Hermann ; Sopala, Monika ; Corrado, Claudia ; Bengoudifa, Bourras-Rezki ; Binlich, Florence ; Richardson, Paul G
Source
In Lancet Oncology October 2014 15(11):1195-1206
Subject
Primary Research Articles
Language
ISSN
1470-2045